Genomma Lab Internacional, S.A.B. de C.V.
High growth potential and good value.
Share Price & News
How has Genomma Lab Internacional. de's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GEKA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GEKA exceeded the German Pharmaceuticals industry which returned -10.3% over the past year.
Return vs Market: GEKA exceeded the German Market which returned -17.5% over the past year.
Price Volatility Vs. Market
How volatile is Genomma Lab Internacional. de's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Genomma Lab Internacional. de undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GEKA (€0.73) is trading below our estimate of fair value (€1.86)
Significantly Below Fair Value: GEKA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GEKA is good value based on its PE Ratio (18.4x) compared to the Pharmaceuticals industry average (19.3x).
PE vs Market: GEKA is poor value based on its PE Ratio (18.4x) compared to the German market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: GEKA is good value based on its PEG Ratio (0.7x)
Price to Book Ratio
PB vs Industry: GEKA is overvalued based on its PB Ratio (2.2x) compared to the DE Pharmaceuticals industry average (1.6x).
How is Genomma Lab Internacional. de forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GEKA's forecast earnings growth (25.2% per year) is above the savings rate (-0.4%).
Earnings vs Market: GEKA's earnings (25.2% per year) are forecast to grow faster than the German market (14.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GEKA's revenue (8.8% per year) is forecast to grow faster than the German market (4.2% per year).
High Growth Revenue: GEKA's revenue (8.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GEKA's Return on Equity is forecast to be high in 3 years time (20.5%)
How has Genomma Lab Internacional. de performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GEKA has high quality earnings.
Growing Profit Margin: GEKA's current net profit margins (7.7%) are lower than last year (9.4%).
Past Earnings Growth Analysis
Earnings Trend: GEKA's earnings have grown by 19.4% per year over the past 5 years.
Accelerating Growth: GEKA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GEKA had negative earnings growth (-11.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (1.9%).
Return on Equity
High ROE: GEKA's Return on Equity (12%) is considered low.
How is Genomma Lab Internacional. de's financial position?
Financial Position Analysis
Short Term Liabilities: GEKA's short term assets (MX$10.0B) exceed its short term liabilities (MX$5.6B).
Long Term Liabilities: GEKA's short term assets (MX$10.0B) exceed its long term liabilities (MX$5.5B).
Debt to Equity History and Analysis
Debt Level: GEKA's debt to equity ratio (73.2%) is considered high.
Reducing Debt: GEKA's debt to equity ratio has increased from 65.8% to 73.2% over the past 5 years.
Debt Coverage: GEKA's debt is not well covered by operating cash flow (16.6%).
Interest Coverage: GEKA's interest payments on its debt are well covered by EBIT (4.3x coverage).
Inventory Level: GEKA has a high level of physical assets or inventory.
Debt Coverage by Assets: GEKA's debt is covered by short term assets (assets are 1.7x debt).
What is Genomma Lab Internacional. de's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GEKA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate GEKA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GEKA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GEKA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: GEKA is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GEKA's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jorge Luis Brake Valderrama
Mr. Jorge Luis Brake Valderrama is the Chief Executive Officer at Genomma Lab Internacional SAB de CV since September 10, 2018. He held the position of Senior Vice President of Global Operations at Laureat ...
|Chief Executive Officer||1.5yrs||no data||no data|
|Executive VP & CFO||no data||no data||no data|
|Executive VP & COO||1.58yrs||no data||no data|
|Head of Investor Relations||no data||no data||no data|
|Legal Officer||no data||no data||no data|
|Executive Vice President of Marketing||2.17yrs||no data||no data|
|Executive Vice-President of Media & Institutional Affairs||no data||no data||no data|
|Chief of Security||no data||no data||no data|
|Secretary||no data||no data||no data|
|Deputy Secretary||2.92yrs||no data||no data|
Experienced Management: GEKA's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Genomma Lab Internacional, S.A.B. de C.V.'s company bio, employee growth, exchange listings and data sources
- Name: Genomma Lab Internacional, S.A.B. de C.V.
- Ticker: GEKA
- Exchange: DB
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: Mex$18.053b
- Listing Market Cap: Mex$692.922m
- Shares outstanding: 1.01b
- Website: https://www.genommalab.com
Number of Employees
- Genomma Lab Internacional, S.A.B. de C.V.
- Antonio Dovali Jaime # 70
- Piso 2 Torre C
- Mexico City
- Distrito Federal
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LAB B||BMV (Bolsa Mexicana de Valores)||Yes||Series B Variable Shares||MX||MXN||Jun 2008|
|GEKA||DB (Deutsche Boerse AG)||Yes||Series B Variable Shares||DE||EUR||Jun 2008|
|GNML.F||OTCPK (Pink Sheets LLC)||Yes||Series B Variable Shares||US||USD||Jun 2008|
Genomma Lab Internacional, S.A.B. de C.V. together with its subsidiaries, engages in the research, development, and marketing of pharmaceutical, over the counter, and cosmetic products in Mexico and internationally. The company was founded in 1996 and is based in Mexico City, Mexico.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/28 22:08|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.